OmniAb Earnings Call Highlights Platform Growth, Cash Path

Omniab, Inc. ((OABI)) has held its Q4 earnings call. Read on for the main highlights of the call.

OmniAb’s latest earnings call painted a cautiously optimistic picture, with management emphasizing strong strategic momentum despite near-term financial pressure. Partner and program growth, new technology platforms, and a multibillion‑dollar milestone backlog are building a foundation for future royalty revenue, even as 2025 revenue declines, losses, and milestone timing uncertainty weigh on the story.

Partner and Program Growth

OmniAb closed 2025 with 107 partners and 407 active programs, a net gain of 44 programs over the year. The company added 84 new programs, more than 20% above 2024 additions, and over 98% of active programs carry contracted future economics, reinforcing the long-term revenue opportunity embedded in its partnered pipeline.

Large Contracted Milestone and Royalty Backlog

Management highlighted more than $3.0 billion in total contracted milestone payments across its antibody portfolio, along with an average royalty rate of roughly 3.4%. While actual cash realization will depend on partner success and timelines, the backlog underscores the scale of potential upside if a meaningful portion of these programs reach the market.

Program Progression and Clinical Momentum

Pipeline advancement remained steady in 2025, with 25 program progression events, including 16 moving from discovery to preclinical and four from preclinical to Phase I. By year-end, OmniAb counted 32 clinical or approved programs backed by more than $350 million in remaining milestones, with high-profile partners like Immunovant, Teva, and Merck KGaA pushing key assets toward late-stage trials.

New Platform Launches — OmniUltra and xPloration

The company expanded its technology stack with OmniUltra, a transgenic chicken platform designed to access ultra-long CDRH3 antibodies and peptide-like molecules, opening new therapeutic niches and outreach to more than 130 potential partners. OmniAb also rolled out its xPloration single B-cell screening platform, deploying two instruments and generating about $800,000 in 2025 revenue as an early proof of concept.

Disciplined Cost Management

Against a backdrop of lumpy top-line trends, OmniAb tightened its cost base, trimming full-year operating expenses to $87.6 million from $100.9 million. R&D and G&A both declined year over year, and a workforce reduction of 22 employees is expected to drive further savings, helping extend runway while the royalty engine is still being built.

Year-End Liquidity

The company ended 2025 with $54 million in cash, cash equivalents, and short-term investments, which management believes is adequate to fund the 2026 operating plan. This liquidity position supports continued investment in platforms and programs while OmniAb works toward a more recurring, royalty-focused revenue mix.

Revenue Decline Year-over-Year

Despite operational progress, financial results reflected the inherent volatility of a milestone-driven model, with Q4 2025 revenue falling to $8.4 million from $10.8 million and full‑year revenue sliding nearly 30% to $18.7 million. Management tied the decline to lower license and milestone revenue and the wind-down of certain small-molecule service work, emphasizing that quarterly revenue will remain uneven.

Sustained Net Loss and Noncash Impairment

OmniAb reported a wider absolute net loss of $64.8 million for 2025, compared with $62.0 million a year earlier, with Q4 losses also expanding. The fourth quarter included a $3.9 million noncash impairment linked to legacy ion channel assets, underscoring the transition away from older small-molecule businesses toward the core antibody and platform strategy.

Program Attrition and Regressions

Not every program moved forward, as the company recorded 40 terminations and four regressions during 2025, which management framed as typical attrition in drug development. Even so, these setbacks are a reminder that not all partnered assets will reach commercialization, adding uncertainty to the timing and magnitude of future milestone and royalty streams.

Nascent Commercialization of xPloration

While xPloration is strategically important, its commercial contribution remains small, with only two instruments placed and less than $1 million in revenue so far. For this platform to become a significant growth driver, OmniAb will need broader adoption and to unlock recurring revenue from consumables, subscriptions, and service contracts over time.

Cash Drawdown and Breakeven Uncertainty

The company expects to exit 2026 with $30–35 million in cash, implying a net drawdown from current levels despite lower operating expenses. Management reiterated that breakeven timing is difficult to pinpoint because it relies heavily on partner progress and milestone triggers, and prior capital raises that increased share count reflect the need to fund the business through this transition.

Modest Average Royalty Rate

OmniAb’s average portfolio royalty rate of about 3.4% is meaningful but implies that large commercial sales will be required to generate substantial recurring royalty income. This structure could delay the point at which royalties alone materially reshape the company’s cash flow profile, even if a number of partnered drugs ultimately succeed.

Forward-Looking Guidance and Path to Cash-Flow Positivity

For 2026, OmniAb guided to revenue of $25–30 million, signaling a rebound from 2025’s depressed levels, alongside GAAP operating expenses of $80–85 million and cash operating expenses of $50–55 million and an expected year-end cash balance of $30–35 million. Longer term, management is leaning on more than $3 billion in contracted milestones, roughly $350 million tied to clinical-stage assets, and a growing royalty base to gradually shift the model toward higher-margin, royalty-driven cash flow, even if the exact breakeven date remains uncertain.

The earnings call reinforced a narrative of solid strategic progress layered over near-term financial strain, a familiar pattern for platform biotech names. For investors, OmniAb’s appeal rests on whether its expanding partnered pipeline and sizable milestone and royalty backlog can eventually overcome current losses and cash burn, turning today’s lumpy revenues into durable, high-margin royalty streams.